Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study
Authors:
- 1 April 2012
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 71 (4) , 534-540
Abstract
Objectives To assess whether therapy to achieve both a disease activity score in 28 joints (DAS28) less than 2.6 and matrix metalloproteinase (MMP) 3 normalisation offers better outcomes than either target alone in early rheumatoid arthritis (RA) at 56 weeks: Treating to Twin Targets (T-4) Study. Methods 243 early RA patients were randomly allocated to one of four strategy groups: routine care (R group; n=62); DAS28-driven therapy (D group; n=60); MMP-3-driven therapy (M group; n=60); or both DAS28 and MMP-3-driven therapy group (twin; T group; n=61). Medication was started with sulfasalazine (1 g/day) in all intervention groups. Targets were DAS28 less than 2.6 for the D group, MMP-3 normalisation for the M group and both DAS28 less than 2.6 and MMP-3 normalisation for the T group. If the value in question did not fall below the previously measured level, medication was intensified, including methotrexate, other disease-modifying antirheumatic drugs and biological agents. Primary, secondary and outcome measures consisted of the proportions of patients showing clinical remission (DAS28 Results Clinical remission at 56 weeks was achieved by more patients in the T group (56%) than in the R group (pConclusions Results of the T-4 Study reveal that a twin target strategy can achieve a high clinical remission rate in early RA.Keywords
This publication has 28 references indexed in Scilit:
- Rapid and sustained improvement in bone and cartilage turnover markers with the anti–interleukin‐6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double‐blind, placebo‐controlled trial of tocilizumab in inadequate responders to methotrexate aloneArthritis & Rheumatism, 2009
- Evidence for predictive validity of remission on long‐term outcome in rheumatoid arthritis: A systematic reviewArthritis Care & Research, 2009
- The Disease Activity Score and the EULAR Response CriteriaRheumatic Disease Clinics of North America, 2009
- Triple therapy in early active rheumatoid arthritis: A randomized, single‐blind, controlled trial comparing step‐up and parallel treatment strategiesArthritis & Rheumatism, 2008
- Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trialThe Lancet, 2007
- The epidemiologic basis for population-wide cholesterol reduction in the primary prevention of coronary artery diseaseThe American Journal of Cardiology, 2004
- Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trialThe Lancet, 2004
- Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritisArthritis Care & Research, 2003
- Awareness, Knowledge, and Attitudes of Older Americans About High Blood PressureArchives of internal medicine (1960), 2003
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988